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Despite concerns about their safety, psy-chotropic medications are used frequentlyto manage behavioural symptoms in older
adults, particularly in those who have dementia.
These medications tend to be used because the
effectiveness of psychosocial and behavioural
interventions remains unclear, and because imple-
mentation of those alternate interventions is often
hampered by a lack of resources.1 In nursing
homes, psychotropic agents are given to up to two-
thirds of dementia patients.2–5
The safety of antipsychotic medications in
older adults has been called into question. The
United States Food and Drug Administration and
Health Canada have issued advisories stating
that certain atypical antipsychotics (risperidone,
olanzapine and aripiprazole) have been associ-
ated with an increased risk of stroke and tran-
sient ischemic events, and both atypical and con-
ventional antipsychotics have been associated
with an increased risk of death.6–11 Given this
problematic safety record, physicians may
increasingly resort to alternative psychotropic
agents for management of behavioural symp-
toms in older adults.1,12,13 However, comparative
studies of the safety of other classes of psy-
chotropic medications in such patients have not
been conducted.
In the absence of randomized controlled trials,
pharmacoepidemiologic studies using large data-
bases are the best option available for defining the
comparative safety of the psychopharmacologic
treatment regimens used to manage behavioural
symptoms in older adults with dementia. Rigorous
methodologic approaches need to be applied to
ensure that epidemiologic studies are unbiased by
the selective prescribing that occurs in nonran-
domized studies.1 We aimed to examine the
Risk of death and hospital admission for major medical
events after initiation of psychotropic medications in older
adults admitted to nursing homes
Krista F. Huybrechts MS PhD, Kenneth J. Rothman DrPH, Rebecca A. Silliman MD PhD, M. Alan Brookhart PhD,
Sebastian Schneeweiss MD ScD
Competing interests: None
declared.
This article has been peer
reviewed.
Correspondence to: 





Background: Despite safety-related concerns,
psychotropic medications are frequently pre-
scribed to manage behavioural symptoms in
older adults, particularly those with dementia.
We assessed the comparative safety of differ-
ent classes of psychotropic medications used
in nursing home residents.
Methods: We identified a cohort of patients
who were aged 65 years or older and had ini-
tiated treatment with psychotropics after
admission to a nursing home in British Colum-
bia between 1996 and 2006. We used propor-
tional hazards models to compare rates of
death and rates of hospital admissions for
medical events within 180 days after treat-
ment initiation. We used propensity-score
adjustments to control for confounders.
Results: Of 10 900 patients admitted to nursing
homes, atypical antipsychotics were initiated
by 1942, conventional antipsychotics by 1902,
antidepressants by 2169 and benzodiazepines
by 4887. Compared with users of atypical
antipsychotics, users of conventional antipsy-
chotics and antidepressants had an increased
risk of death (rate ratio [RR] 1.47, 95% confi-
dence interval [CI] 1.14–1.91 for conventional
antipsychotics and RR 1.20, 95% CI 0.96–1.50
for antidepressants), and an increased risk of
femur fracture (RR 1.61, 95% CI 1.03–2.51 for
conventional antipsychotics and RR 1.29, 95%
CI 0.86–1.94 for antidepressants). Users of ben-
zodiazepines had a higher risk of death (RR
1.28, 95% CI 1.04–1.58) compared with users of
atypical antipsychotics. The RR for heart failure
was 1.54 (95% CI 0.89–2.67), and for pneumo-
nia it was 0.85 (95% CI 0.56–1.31).
Interpretation: Among older patients admit-
ted to nursing homes, the risks of death and
femur fracture associated with conventional
antipsychotics, antidepressants and benzodi-
azepines are comparable to or greater than
the risks associated with atypical antipsy-
chotics. Clinicians should weigh these risks
against the potential benefits when making
prescribing decisions.
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association between various classes of psy-
chotropic medications and a range of unintended
health outcomes among older adults admitted to
nursing homes. We focused on patients in nursing
homes because use of psychotropic medication is
known to be extensive in this setting,2–5 and med-
ication safety is of particular concern given the
complex array of medical illnesses among these
patients.
Methods
Study design and data source
We conducted a population-based cohort study
involving older adults newly admitted to a nursing
home in the province of British Columbia (BC).
We obtained ethics approval for our study from
the Brigham and Women’s Hospital Institutional
Review Board.
We used linked administrative data from the BC
Ministry of Health. The data included longitudinal,
person-specific information on health services
received under the province’s universal insurance
program, including physician services, admissions
to hospital and long-term care, and prescription
drugs recorded as dispensed by the province-wide
PharmaNet database. Vital status information was
linked from the BC Vital Statistics Agency.
Study cohort and medications
The study cohort consisted of all BC residents aged
65 years or older who were admitted to a nursing
home between Jan. 1, 1996, and Mar. 31, 2006,
and who were prescribed a psychotropic medica-
tion during the first 90 days after admission but not
during the six months before admission. We
employed a new-user design to avoid underascer-
tainment of events occurring soon after therapy
begins,14 and to ensure that baseline covariables at
study entry were assessed before treatment initia-
tion and not affected by the treatment itself.15
We classified patients into one of four treatment
categories (atypical antipsychotics, conventional
antipsychotics, antidepressants, or benzodiazepines
and other hypnotic agents [referred to as benzodi-
azepines]) according to the first new prescription
for a psychotropic agent that was filled within the
90-day enrollment window. The specific medica-
tions that comprised each category are listed in
Appendix 1 (available at www .cmaj .ca /cgi /content
/full /cmaj .101406 /DC1).
The date of initiation of treatment was consid-
ered to be the index date. We excluded patients
who, on the index date, filled prescriptions for mul-
tiple medications that belonged to different
psychotropic classes. We also excluded patients
with a diagnosis of cancer before the index date to
avoid residual confounding introduced by selective
prescribing of conventional antipsychotics as
antiemetics for patients undergoing chemotherapy.10
Exposure to a class of psychotropic medication was
considered to be discontinued if the prescription
had not been refilled 14 days after the end of the last
dispensed supply.
Baseline covariables were assessed during the
six-month period before (and inclusive of) the
index date. The period of follow-up began the day
after the index date and extended up to 180 days.
Outcome measures
Selection of outcomes was informed by the safety
concerns that have been raised for antipsychotics.
All noncancer deaths occurring within 180 days
after the index date were identified. Other outcomes
included cardiac events (myocardial infarction, heart
failure, cardiac arrest and ventricular arrhythmias),
cerebrovascular events (ischemic stroke and tran-
sient ischemic attack), femur fracture, pneumonia
and venous thromboembolism. Events were defined
based on admission to hospital within 180 days after
the index date with a relevant primary or secondary
International Classification of Diseases (ICD) diag-
nostic or procedural code based on the 9th revision,
clinical modification (ICD-9-CM) or the ICD-10
(Appendix 2, available at www .cmaj .ca /cgi /content
/full /cmaj .101406 /DC1).
Potential confounders
Potential confounding variables included age, sex,
calendar year, level of care assigned at the time of
admission to a nursing home, and clinical conditions
that might affect the outcomes under consideration.
Psychiatric morbidity was defined as dementia,
depression, anxiety, delirium, a mood disorder, a
psychotic disorder, a sleep disorder, alcohol or drug
abuse, other psychiatric disorders, or prior use of
anticholinergic and psychotropic drugs. Other
comorbid conditions included hypertensive heart
and kidney diseases, arrhythmias (a diagnosis plus
use of antiarrhythmia medication), diabetes mellitus
(a diagnosis plus use of antidiabetic medications),
cerebrovascular disease (hemorrhagic and ischemic
events), congestive heart failure, acute myocardial
infarction, coronary artery disease, other evidence
of ischemic heart disease (angina, percutaneous
transluminal coronary angioplasty, coronary artery
bypass graft or nitroglycerin use), other cardiovas-
cular conditions (including valvular disease,
aneurysm, peripheral vascular disease), HIV infec-
tion, epilepsy, Parkinson disease, osteoporosis,
fracture history, pneumonia and chronic lung dis-
ease. We used the Charlson comorbidity index,16
number of physician visits for any reason, number
of hospital admissions for any reason and of any
length, number of distinct (nonpsychotropic) pre-
scription drugs, and prior specialist care (i.e.,
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psychiatrist, geriatrician or neurologist) as generic
markers of comorbidity.17
Statistical analysis
We calculated the rates of the various outcomes
with follow-up censored at the time of treatment
discontinuation (plus a 30-day lag period) or
treatment crossover, defined as a switch to or
addition of a medication belonging to the com-
parator group (i.e., as-treated analysis).
We fit proportional hazards models for pairwise
comparisons against atypical antipsychotics. We
used propensity score adjustment to balance mea-
sured risk factors for the outcomes between
medication user groups.18 Propensity scores were
derived from predicted probabilities estimated in
logistic regression models of conventional antipsy-
chotic, antidepressant and benzodiazepine use
versus atypical antipsychotic use. The propensity
score models contained all of the potential con-
founders listed above, except those that were
known to be strongly related to the exposure and
thought to be unrelated to the outcomes. The latter
were excluded to avoid unnecessarily increasing
the variance of the estimated exposure effect19 and
to reduce bias through adjustment for an instru-
mental variable in the presence of unmeasured
confounders.20
We truncated 2.5% of patients on either
extreme of the propensity score distribution, and
divided patients into quintiles based on their
propensity score value. The Cox models were
adjusted for these quintiles. This approach ensured
that the comparisons were made between patients
that were homogeneous in terms of measured
sociodemographic characteristics, health care uti-
lization characteristics and medical history,
including proxies for treatment indication (Appen-
dix 3, available at www .cmaj .ca /cgi /content /full
/cmaj .101406 /DC1). Treatment with another psy-
chotropic medication class after the index date was
included as a time-varying covariable. Adjusted
models were run separately in strata defined by
dementia, and for patients with no prior use of
either the treatment or comparator medication
class. We also investigated the effect of restricting
the group of patients initiating benzodiazepines to
those who received medications used primarily to
manage anxiety and agitation (as opposed to those
used primarily to induce sleep).
In secondary analyses, we used high-dimen-
sional propensity score adjustment in an effort to
further reduce residual confounding.21 The high-
dimensional propensity score algorithm evaluated
thousands of diagnoses, procedures and pharmacy
claim codes (referred to as data dimensions) to
identify and prioritize covariables that served as
proxies for unmeasured confounders, such as level
of cognitive functioning, dependence in activities
of daily living and severity of behavioural distur-
bances. Specifically, the 200 most prevalent codes
in each data dimension were prioritized by calcu-
lating, for each covariable, the possible amount of
confounding it could adjust for in a multiplicative
model, given a binary exposure and outcome, after
adjusting for demographic covariables. These
covariables were then sorted in descending order of
confounding potential, and the top 500 empirical
covariables were selected. These empirically iden-
tified confounders were combined with investigator-
identified covariables to improve confounding
adjustment. We also conducted analyses that carried
the first exposure forward throughout the 180 days
(initially-treated analysis).
Results
Of the 10 900 patients included in the study
cohort, 1942 initiated an atypical antipsychotic,
1902 a conventional antipsychotic, 2169 an anti-
depressant and 4887 a benzodiazepine. Most
patients initiated treatment shortly after admission
(median 1 day, interquartile range 0–13 days).
Overall, users of atypical antipsychotics had
more diagnosed psychiatric comorbidities, used
more medications indicated for dementia and psy-
chotropic medications, and had more visits to
psychiatrists (Table 1). Compared with users of
atypical antipsychotics, users of conventional
antipsychotics had fewer comorbidities and
required less intensive care. Users of antidepressants
were sicker than users of atypical antipsychotics,
with considerably more pre-existing diseases of the
circulatory system, diabetes, chronic lung disease
and prior fractures, and with worse general indi-
cators of comorbidity. Users of benzodiazepines
had more pre-existing cardiovascular disease, dia-
betes, chronic lung disease and fractures than
users of atypical antipsychotics, but general indi-
cators of comorbidity indicated they were in
slightly better health otherwise.
Rates of noncancer-related mortality, femur
fracture, heart failure and stroke were lower
among patients who initiated atypical antipsy-
chotics than among those who initiated other
psychotropic medications. The rate of myocardial
infarction was higher (Table 2). Cardiac arrest,
ventricular arrhythmia and venous thromboem-
bolism were uncommon events, with rates well
below one per 100 person-years in all groups.
Owing to the low number of events observed,
these event types, as well as stroke and myocardial
infarction, were not included in the final analysis.
The time from treatment initiation to occur-
rence of events is shown in Figure 1. The
corresponding rate ratios (RRs) are shown in
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Table 1: Characteristics of the study cohort, stratified by class of medication (part 1 of 2) 
 No. (%)* 
Characteristic 
Atypical antipsychotics  
n = 1942 
Conventional antipsychotics 
n = 1902 
Antidepressants 
n = 2169 
Benzodiazepines 
n = 4887 
Sex, male 811  (41.8) 852  (44.8) 832 (38.4) 1876  (38.4) 
Age, yr, mean (SD) 84.0 (6.6) 83.0 (6.8) 83.6 (6.9) 84.0 (7.0) 
Year index prescription filled         
1996–2000 515  (26.5) 1275  (67.0) 1085  (50.0) 2714  (55.5) 
2000–2006 1427  (73.5) 627 (33.0) 1084  (50.0) 2173  (44.5) 
Nursing home care level†         
Personal care or intermediate care 1 5  (0.3) 8  (0.5) 23  (1.0) 60  (1.2) 
Intermediate care 2 334  (17.2) 498  (26.2) 681  (31.4) 1608  (32.9) 
Intermediate care 3 1241  (63.9) 1115  (58.6) 952  (43.9) 2297  (47.0) 
Extended care 362  (18.6) 281  (14.8) 513  (23.7) 922 (18.9) 
Cardiovascular comorbidities         
Cardiac arrhythmia 22  (1.1) 17  (0.9) 34 (1.6) 73  (1.5) 
Congestive heart failure 219  (11.3) 201  (10.6) 328 (15.1) 736  (15.1) 
Hypertension 384  (19.8) 314  (16.5) 516  (23.8) 942  (19.3) 
Ischemic heart disease         
Myocardial infarction 66 (3.4) 76  (4.0) 113  (5.2) 246  (5.0) 
Coronary artery disease 104  (5.4) 89 (4.7) 189  (8.7) 326  (6.7) 
Other ischemic heart disease‡ 294  (15.1) 253  (13.3) 444 (20.5) 948  (19.4) 
Peripheral arterial disease 38  (2.0) 28  (1.5) 81  (3.7) 106  (2.2) 
Valvular disease 35  (1.8) 29  (1.5) 42  (1.9) 85  (1.7) 
Cerebrovascular disease 296  (15.2) 261  (13.7) 456  (21.0) 715  (14.6) 
Psychiatric comorbidites         
Dementia 1092  (56.2) 947  (49.8) 650  (30.0) 1354  (27.7) 
Depression 218  (11.2) 176 (9.3) 459 (21.2) 341  (7.0) 
Delirium 328  (16.9) 228  (12.0) 181  (8.3) 277  (5.7) 
Mood disorder 60  (3.1) 24  (1.3) 80 (3.7) 77  (1.6) 
Psychotic disorder 529  (27.2) 368  (19.3) 251  (11.6) 537  (11.0) 
Anxiety 18  (0.9) 13 (0.7) 40 (1.8) 42  (0.9) 
Other comorbidities         
Diabetes 160 (8.2) 160  (8.4) 297  (13.7) 457  (9.4) 
Parkinson disease 85  (4.4) 51  (2.7) 118  (5.4) 194  (4.0) 
Epilepsy 22  (1.1) 28  (1.5) 22  (1.0) 49  (1.0) 
Pneumonia 158  (8.1) 143  (7.5) 197  (9.1) 422  (8.6) 
Chronic lung disease 163  (8.4) 139  (7.3) 248  (11.4) 498  (10.2) 
Osteoporosis 102  (5.3) 77  (4.0) 170  (7.8) 264  (5.4) 
Fracture 251  (12.9) 221  (11.6) 293  (13.5) 671  (13.7) 
History of psychotropic medication use       
Atypical antipsychotics 0 (0.0) 230 (12.1) 151 (7.0) 426  (8.7) 
Conventional antipsychotics 122  (6.3) 0  (0.0) 94  (4.3) 199  (4.1) 
Antidepressants 414  (21.3) 307  (16.1) 0 (0.0) 767  (15.7) 
Benzodiazepines 369  (19.0) 332  (17.5) 426  (19.6) 0  (0.0) 
Anticonvulsants 74  (3.8) 63  (3.3) 68  (3.1) 154  (3.2) 
Medications for Alzheimer disease  380  (19.6) 181 (9.5) 178 (8.2) 395  (8.1) 
Table 3. Patients who initiated conventional
antipsychotics had a higher risk of noncancer-
related death than users of atypical antipsychotics
(RR 1.47, 95% CI 1.14–1.91), as well as an
increased risk of femur fracture (1.61, 95% CI
1.03–2.51). The RR for pneumonia (1.03, 95% CI
0.62–1.69) and heart failure (0.91, 95% CI 0.41–
2.01) were near null.
Among patients who initiated antidepressants,
the associations for noncancer-related death (1.20,
95% CI 0.96–1.50) and femur fracture (1.29, 95%
CI 0.86–1.94) were considerably weaker, and the
associations for pneumonia (1.09, 95% CI 0.73–
1.65) and heart failure (1.04, 95% CI 0.60–1.80)
were near null.
Patients who initiated benzodiazepines were at
increased risk for noncancer-related death (1.28,
95% CI 1.04–1.58). Virtually no difference was
observed in the risk of femur fracture (0.99, 95%
CI 0.66–1.51). The RR for pneumonia was 0.85
(95% CI 0.56–1.31). Users of benzodiazepines
had an increased risk of admission to hospital for
heart failure in the unadjusted analysis (RR 2.59).
This association was reduced to 1.54 (95% CI
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Table 1: Characteristics of the study cohort, stratified by class of medication (part 2 of 2) 
 No. (%)* 
Characteristic (cont.) 
Atypical antipsychotics  
n = 1942 
Conventional antipsychotics 
n = 1902 
Antidepressants 
n = 2169 
Benzodiazepines 
n = 4887 
General indicators of 
comorbidity§ 
        
Charlson comorbidity index score, 
mean (SD)** 
1.20  (1.28) 1.12  (1.28) 1.36  (1.56) 1.06  (1.38) 
Admitted to hospital 1296  (66.7) 1242  (65.3) 1547  (71.3) 3091  (63.2) 
Visited a neurologist 145  (7.5) 152  (8.0) 246  (11.3) 407  (8.3) 
Visited a psychiatrist 643  (33.1) 464  (24.4) 485  (22.4) 657  (13.4) 
Visited a geriatrician 232  (11.9) 218  (11.5) 198  (9.1) 344  (7.0) 
Number of physician visits, mean (SD) 21.0  (17.2) 16.7  (15.0) 22.8  (18.7) 18.2  (15.9) 
Number of prescription drugs,  
mean (SD) 
9.0  (6.2) 7.5  (5.7) 10.5 (6.5) 9.4  (6.5) 
*Unless otherwise indicated. 
†Indicates the care level used to define a patient’s functional abilities. Personal care and intermediate care 1 were assigned to patients with low-care needs, 
whereas intermediate care 2, intermediate care 3 and extended care levels indicate increasingly higher care requirements. 
‡Includes other acute and subacute forms of ischemic heart disease (International Classification of Diseases-9 [ICD-9] code 411) and angina pectoris (ICD-9 code 
413). 
§Based on the period of 180 days before the index date.  
**Individual comorbidities were defined based on at least one hospital admission or at least two outpatient visits with the respective ICD codes. 
Table 2: Death and major medical events leading to hospital admission within 180 days after start of psychotropic medication, by 
class of medication  




n = 1942 
Conventional 
antipsychotics 
n = 1902 
Antidepressants 
n = 2169 
Benzodiazepines 
n = 4887 
Death 181/664.3 (27.3) 170/438.8 (38.8) 260/790.4 (32.9) 420/1026.0 (40.9) 
Myocardial infarction 15/662.5 (2.3) 2/438.6 (0.5) 5/790.4 (0.6) 21/1024.8 (2.1) 
Heart failure 23/661.1 (3.5) 19/437.5 (4.3) 56/783.3 (7.2) 103/1017.0 (10.1) 
Cardiac arrest 1/664.3 (0.2) 2/438.8 (0.5) 2/790.4 (0.3) 1/1026.0 (0.1) 
Ventricular arrhythmia 0/664.3 (0.0) 0/438.8 (0.0) 2/790.0 (0.3) 1/1025.8 (0.1) 
Stroke 8/663.8 (1.2) 9/438.2 (2.1) 21/788.2 (2.7) 31/1022.6 (3.0) 
Venous thromboembolism 4/663.6 (0.6) 3/438.6 (0.7) 1/790.2 (0.1) 2/1025.6 (0.2) 
Pneumonia 50/657.2 (7.6) 43/434.0 (9.9) 75/780.9 (9.6) 97/1017.9 (9.5) 
Femur fracture 56/656.0 (8.5) 56/431.2 (13.0) 83/776.0 (10.7) 99/1014.7 (9.8) 
*The events and person-years presented are those used in the comparison with conventional antipsychotics (i.e., patients were censored when they discontinued 
the index treatment or when they switched to or added treatment with a conventional antipsychotic). 
0.89–2.67) after adjustment for differences in pre-
existing cardiovascular disease. When restricting
the analyses to users of benzodiazepine medica-
tions primarily prescribed for anxiety, we
confirmed the findings for noncancer-related
death (1.42, 95% CI 1.12–1.81) and heart failure
(1.93, 95% CI 1.03–3.60). The result for pneumo-
nia was essentially unchanged; for femur fracture,
the RR was 1.23 (95% CI 0.78–1.94).
Results from the initially-treated analysis were
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Figure 1: Unadjusted Kaplan–Meier estimates of the probability of no events over time, by psychotropic medication class 
consistent with the findings from the as-treated
analyses, although the effects tended to be attenu-
ated (Appendix 4, available at www.cmaj.ca /cgi
/content /full/cmaj .101406 /DC1). The RR for non-
cancer-related death did not differ meaningfully for
those with and without a diagnosis of dementia.
Restrictions to the subgroup of patients with no
prior use of either the treatment or comparator class
of medication did not meaningfully affect the asso-
ciations for any of the outcomes. Likewise, in most
cases, analyses using high-dimensional propensity
score adjustments yielded no substantive changes.
They tended to move the estimates toward the null
(Table 3). Finally, by way of a sensitivity analysis,
we evaluated deaths not expected to be causally
related to the exposures. The distribution of causes
of death is shown in Appendix 5 (available at www
.cmaj .ca /cgi /content /full /cmaj .101406 /DC1). Such
causes included certain infectious and parasitic dis-
eases; diseases of the blood and blood-forming
organs; diseases of the digestive system; diseases
of the genitourinary system; diseases of the skin and
subcutaneous tissue; diseases of the musculoskele-
tal system and connective tissue; and symptoms,
signs and abnormal clinical and laboratory findings
not classified elsewhere. As expected, we observed
effect estimates consistent with a null association
for all three comparisons.
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Table 3: Rate ratios for selected health outcomes within 180 days after initiation of therapy with psychotropic medication 
 RR (95% CI) 
Variable Death  Femur fracture Pneumonia Heart failure 
Conventional v. atypical antipsychotics         
Unadjusted 1.37 (1.11–1.69) 1.47 (1.01–2.13) 1.18 (0.78–1.78) 1.18 (0.64–2.18) 
Adjusted         
 Age, sex and calendar year 1.47 (1.13–1.90) 1.58 (1.02–2.44) 0.98 (0.60–1.59) 1.32 (0.62–2.84) 
 Propensity score 1.47 (1.14–1.91) 1.61 (1.03–2.51) 1.03 (0.62–1.69) 0.91 (0.41–2.01) 
 High-dimensional propensity score 1.52 (1.14–2.02) 1.49 (0.93–2.41) 0.94 (0.56–1.58) 0.81 (0.36–1.85) 
Propensity score adjusted by patient subgroup         
 No history of either treatment* 1.33 (0.99–1.77) 1.67 (1.03–2.71) 0.94 (0.55–1.63) 0.95 (0.41–2.17) 
 Dementia† 1.37 (0.96–1.95)       
 No dementia 1.61 (1.10–2.36)       
Antidepressants v. atypical antipsychotics         
Unadjusted 1.25 (1.03–1.52) 1.31 (0.92–1.85) 1.31 (0.91–1.88) 1.92 (1.19–3.07) 
Adjusted         
 Age, sex and year 1.34 (1.10–1.64) 1.26 (0.87– 1.81) 1.29 (0.88–1.89) 1.88 (1.15–3.08) 
 Propensity score 1.20 (0.96–1.50) 1.29 (0.86–1.94) 1.09 (0.73–1.65) 1.04 (0.60–1.80) 
 High-dimensional propensity score 1.20 (0.95–1.51) 1.24 (0.81–1.91) 0.89 (0.58–1.39) 0.80 (0.45–1.42) 
Propensity score adjusted by patient subgroup         
 No history of either treatment* 1.24 (0.97–1.59) 1.46 (0.91–2.34) 1.24 (0.76–2.02) 1.00 (0.53–1.88) 
 Dementia†  1.22 (0.88–1.70)       
 No dementia 1.19 (0.88–1.61)       
Benzodiazepines v. atypical antipsychotics         
Unadjusted 1.37 (1.14–1.64) 1.13 (0.80–1.60) 1.13 (0.79–1.61) 2.59 (1.61–4.16) 
Adjusted         
 Age, sex and year 1.52 (1.25–1.85) 0.98 (0.68–1.42) 0.99 (0.67–1.46) 2.49 (1.51– 4.12) 
 Propensity score 1.28 (1.04–1.58) 0.99 (0.66–1.51) 0.85 (0.56–1.31) 1.54 (0.89– 2.67) 
 High-dimensional propensity score 1.20 (0.96–1.50) 1.13 (0.73–1.75) 0.83 (0.54–1.28) 1.29 (0.71–2.35) 
Propensity score adjusted by patient subgroup         
 No history of either treatment* 1.17 (0.92–1.48) 1.04 (0.64–1.70) 0.78 (0.49–1.24) 1.87 (0.98–3.57) 
 Dementia†  1.21 (0.87–1.68)       
 No dementia 1.35 (1.02–1.80)       
Note: CI = confidence interval, RR = incidence rate ratio. 
*Indicates patients without a history of use of either the referent (atypical antipsychotics) or comparator medication (conventional antipsychotics, antidepressants 
or benzodiazepines). 
†Because of the small number of events, subgroup analyses could not be run for nonmortality outcomes. 
Interpretation
In 10 900 older adults newly admitted to nursing
homes in BC who began taking psychotropic
medications, we observed risks of death that were
higher among those who initiated conventional
antipsychotics, antidepressants and benzodi-
azepines. We also observed risks of femur fracture
that were higher with conventional antipsychotics,
antidepressants and benzodiazepines used for anx-
iety, all compared with atypical antipsychotics. No
clinically meaningful differences were observed
for risk of pneumonia or heart failure, except pos-
sibly a lower risk of pneumonia and a higher risk
of heart failure with benzodiazepines.
The increased risk of noncancer-related death
observed for conventional antipsychotics is consis-
tent with earlier findings.10,11,22,23 We did not confirm
the finding from an earlier study involving commu-
nity-dwelling patients24 in which users of atypical
agents showed a greatly increased risk of pneumo-
nia compared with users of conventional agents.
Our finding of a higher risk of femur fracture
among users of conventional antipsychotics than
among users of atypical agents is in line with obser-
vations made by Rochon and colleagues25 regarding
admissions to hospital for falls and fractures during
the first 30 days after initiation of antipsychotic
treatment among nursing home residents. In con-
trast, similar relative increases in risk among users
of atypical and conventional antipsychotics com-
pared with nonusers were found in a case–control
study.26 The risk of heart failure among users of
antipsychotics and the comparative safety of anti-
depressants and benzodiazepines versus atypical
antipsychotics have not been examined previously.
Limitations
As with any nonrandomized study, there is potential
for residual confounding. We controlled for calendar
year, sociodemographic characteristics, clinical fac-
tors and health care utilization factors that were
likely to be independent predictors of adverse health
outcomes. Nondifferential misclassification of con-
founders typically leads to incomplete adjustment of
confounding bias.27 No information was available on
cognitive and functional impairment, or on severity
of behavioural disturbances. High-dimensional
proxy adjustment based on propensity score tech-
niques was used in an effort to improve control of
confounding compared with adjustment limited to
predefined covariables.28
Except for mortality, there is likely to be under-
ascertainment of the outcomes. Because we
implemented strict disease definitions to maxi-
mize specificity, we expect the relative measures
of effect to be unbiased.29 Lack of consumption of
filled prescriptions could lead to misclassification
of exposure status. Compliance should be high in
a population of nursing home patients that is
closely monitored, but occasional use might be an
important source of misclassification. Despite the
population-based nature of this study, its limited
cohort size resulted in imprecisely estimated asso-
ciations for some outcomes. Our interpretation
took this into account along with competing
explanations, such as uncontrolled confounding or
selection biases, separating the interpretation of
precision from effect size.30–32 Moreover, the find-
ing that some of these outcomes were rare is of
clinical relevance in itself. Owing to the limited
cohort size, we were unable to assess the effect of
individual drugs, relevant subclasses, or dose.
Potential mechanisms for the observed associa-
tions remain speculative (Appendix 6, available at
www .cmaj .ca /cgi /content /full /cmaj .101406 /DC1).
Conclusion
Our exploratory study adds to the growing evi-
dence that conventional antipsychotics may be no
safer for vulnerable older adults than atypical
antipsychotics. In addition, our findings suggest
that some of the other classes of psychotropic
medications may carry similar risks. While await-
ing confirmation of these initial findings —
ideally in the context of a large randomized trial
— clinicians considering these medications for
their older nursing home patients should weigh
these increased risks against potential benefits
when making prescribing decisions.
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